NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Ascending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
67457-0833-06 | 67457-0833 | pegfilgrastim | Fulphila | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | July 9, 2018 | In Use | |
50242-0077-01 | 50242-0077 | Trastuzumab and Hyaluronidase-oysk | Herceptin Hylecta | 10000.0 U/5mL, 10000.0 U/5mL, 600.0 mg/5mL | Immunotherapy | Monoclonal Antibody | HER2 | Subcutaneous | Feb. 28, 2019 | In Use | |
50242-0109-01 | 50242-0109 | Rituximab and hyaluronidase | Rituxan Hycela | 2000.0 U/mL, 2000.0 U/mL, 120.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Subcutaneous | June 22, 2017 | In Use | |
62756-0452-36 | 62756-0452 | Octreotide acetate | BYNFEZIA Pen | 2.5 mg/mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | April 29, 2020 | In Use | ||
62756-0452-37 | 62756-0452 | Octreotide acetate | BYNFEZIA Pen | 2.5 mg/mL | Hormonal Therapy | Somatostatin Analog | Subcutaneous | April 29, 2020 | In Use | ||
00185-7400-14 | 00185-7400 | Leuprolide Acetate | Leuprolide Acetate | 1.0 mg/.2mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan. 6, 2011 | In Use | ||
00185-7400-85 | 00185-7400 | Leuprolide Acetate | Leuprolide Acetate | 1.0 mg/.2mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug. 4, 1998 | In Use | ||
62935-0222-05 | 62935-0222 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug. 26, 2002 | April 26, 2019 | In Use | ||
62935-0302-30 | 62935-0302 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | Feb. 26, 2003 | April 26, 2019 | In Use | ||
62935-0752-75 | 62935-0752 | Leuprolide Acetate | Eligard | Hormonal Therapy | GnRH Agonist | Subcutaneous | May 15, 2002 | April 26, 2019 | In Use |
Found 10,000 results in 17 milliseconds — Export these results